Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Fermenta Biotech Ltd - 506414 - Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations 2015 - Signing Of Binding Term Sheet For Real Estate Development Of The Company

 Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby inform you that Fermenta Biotech Limited ('Fermenta') has signed a Binding Term Sheet with Mextech Property Developers LLP ('Mextech') on January 31, 2022
31-01-2022
Bigul

Fermenta Biotech Ltd - 506414 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 at the meeting of the Board of Directors held on January 31, 2022 This is in continuation to our letter dated October 11, 2021 intimating the approval of the Board of Directors of the Company to the Composite Scheme of Amalgamation and Arrangement amongst DVK Investments Private Limited ('DVK' or the 'Transferor Company 1') and Aegean Properties Limited ('APL' or the 'Transferor Company 2') and Fermenta Biotech Limited ('FBL' or the 'Transferee Company' or 'the Company') and their respective shareholders (hereinafter referred to as "Scheme").
31-01-2022
Bigul

Fermenta Biotech Ltd - 506414 - Shareholding for the Period Ended December 31, 2021

 Fermenta Biotech Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here
20-01-2022
Bigul

Fermenta Biotech Ltd - 506414 - Regarding Licensing Of Proprietary Biocatalytic Technology For Synthesis Of Molnupiravir And Supply Of Enzyme.

 Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby inform you the following: The Company has signed an Agreement for License of Technology and Supply of Enzyme on January 20, 2022 ('Agreement') with Aurigene Pharmaceutical Services Limited (APSL), a step down subsidiary of Dr. Reddy's Laboratories Limited (DRL) ['Agreement'] whereby the Company will exclusively license its proprietary biocatalytic technology for synthesis of Molnupiravir and supply its enzyme, Candida Antarctica B Lipase (CAL B), to APSL. APSL will exclusively procure the enzyme from FBL. A copy of the press release in this regard is enclosed herewith. This is for your information and records.
20-01-2022
Bigul

Fermenta Biotech Ltd - 506414 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Certificate under Regulation 74(5) of SEBI (Depositories and Participants), Regulations 2018 for the quarter ended December 31, 2021 ('Period') Pursuant to the provisions of Regulation 74(5) of SEBI (Depositories and Participants), Regulations 2018, for the quarter ended December 31, 2021, we hereby certify that on receipt of securities for dematerialization - a. The securities comprised in the said certificate(s) of security have been listed on the stock exchanges where the earlier securities are listed; b. The said certificate(s) after due verification have been mutilated and cancelled and the name of the depositories have been substituted in the register of members as the registered owner.
14-01-2022
Bigul

Fermenta Biotech Ltd - 506414 - Statement Of Investor Complaints For The Quarter Ended December 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- SRIKANT N SHARMADesignation :- Company Secretary and Compliance Officer
13-01-2022
Bigul

Fermenta Biotech Ltd - 506414 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be interacting with the Analyst / Institutional Investor over conference call on Tuesday, January 4, 2022, to discuss the financial performance of the Company for the quarter and half year ended September 30, 2021 ['H1/Q2FY22']. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This information is submitted to you pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Kindly note that changes may happen due to exigencies on the part of Host / Company.
03-01-2022
Bigul

Fermenta Biotech Ltd - 506414 - Closure of Trading Window

 Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, Company''s Code of Conduct for Prevention of Insider Trading, BSE circular no. LIST/COMP/01/2019-20 dated April 2, 2019 regarding intimation for closure of Trading Window, it is hereby notified that the 'Trading Window' (period for trading in Company's securities) will be closed with effect from January 01, 2022 till 48 hours after the declaration of financial results for the quarter and nine months ended December 31, 2021, as may be approved at the concerned Board Meeting. During the closure of Trading Window, all Directors, Promoters, Insiders, Designated Persons including Auditors shall not, directly or indirectly trade or deal or enter into any transaction involving sale or purchase of the Company's equity shares, either in their own name or in the name of their immediate relatives. The intimation regarding the Board Meeting date will be announced in due course.
29-12-2021
Bigul

Fermenta Biotech Ltd - 506414 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be interacting with the Analyst / Institutional Investor over conference call on Friday, December 24, 2021, to discuss the financial performance of the Company for the quarter and half year ended September 30, 2021 ['H1/Q2FY22']. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This information is submitted to you pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Kindly note that changes may happen due to exigencies on the part of Host / Company.
23-12-2021
Bigul

Fermenta Biotech Ltd - 506414 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby enclose a copy of Investor Relations Presentation for December 2021 for your information. The said Investor Presentation will thereafter be uploaded on Company's website at www.fermentabiotech.com This information is submitted to you pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.
15-12-2021
Next Page
Close

Let's Open Free Demat Account